CLINICAL STUDY ON MITOXANTRONE CONTAINED REGIMEN
FOR TREATMENT IN NEWLY DIAGNOSED CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA
Wan WQ, Yiu XY
Department of
Pediatrics, The Second Hospital of Xiangya School of Medicine, Central
South University. Changsha, China
Objective: a clinical study was conducted in
order to evaluate the efficacy and safety of mitoxantrone in newly
diagnosed childhood acute lymphocytic leukemia.
Methods: Fivety patients with newly diagnosed
childhood acute lymphocytic leukemia received VMLP regimen for inducing
remission, in which mitoxantrone was given 6mg/m2 weekly for 4 weeks. These
patients also received VMLP regimen each 6 months for intensive therapy.
Other 35 patients for control received VDLP regimen. The efficacy and side
effects were analyzed in two groups.
Results: 45 patients achieved complete remission
after treatment for two weeks and the other 5 patients achieves complete
remission at four weeks in group received VMLP regimen. In VMLP group, the
rate of relapse was less, and the main side effect was myelosuppression. The
duration of neutropenia and thrombocytopenia was longer in VMLP treated
patients when compared to control, but there were no significant
differences between two groups in the rates of early death and degree of
organ toxicity except cardiac toxicity. No significant cardiac toxicity was
not observed in VMLP group.
Conclusions: Mitoxantrone contained regimen is
effective in the treatment of childhood acute lymphocytic leukemia.
Mitoxiantrone should be considered for first ¨Cline therapy in ALL.